Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Operating Leases (2023 - 2025)

Historic Operating Leases for China SXT Pharmaceuticals (SXTC) over the last 3 years, with Q1 2025 value amounting to $176648.0.

  • China SXT Pharmaceuticals' Operating Leases fell 2510.09% to $176648.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $176648.0, marking a year-over-year decrease of 2510.09%. This contributed to the annual value of $176648.0 for FY2025, which is 2510.09% down from last year.
  • Latest data reveals that China SXT Pharmaceuticals reported Operating Leases of $176648.0 as of Q1 2025, which was down 2510.09% from $235848.0 recorded in Q1 2024.
  • Over the past 5 years, China SXT Pharmaceuticals' Operating Leases peaked at $306050.0 during Q1 2023, and registered a low of $176648.0 during Q1 2025.
  • In the last 3 years, China SXT Pharmaceuticals' Operating Leases had a median value of $235848.0 in 2024 and averaged $239515.3.
  • Per our database at Business Quant, China SXT Pharmaceuticals' Operating Leases plummeted by 2293.81% in 2024 and then tumbled by 2510.09% in 2025.
  • China SXT Pharmaceuticals' Operating Leases (Quarter) stood at $306050.0 in 2023, then decreased by 22.94% to $235848.0 in 2024, then fell by 25.1% to $176648.0 in 2025.
  • Its Operating Leases stands at $176648.0 for Q1 2025, versus $235848.0 for Q1 2024 and $306050.0 for Q1 2023.